Back to today’s briefing

Story perspectives

Foundayo prescriptions lag; shares drop, forecast cut

4/25/2026

50 7 Full Breakdown

Summary

Story summary

Foundayo was prescribed 3,707 times in its second week, while Wegovy recorded 3,071 prescriptions in its first full week and 18,410 the following week.
Eli Lilly shares fell 2.6% at 9:35 a.m. in New York, while Novo Nordisk shares rose 4% in Denmark.
Analysts said the slower ramp would be viewed negatively, prompting investors to cut Foundayo’s 2026 sales forecast to $1.3-$1.5 billion, a level needing about 300,000 prescriptions by year-end.

1 of 1

Story summary

Foundayo was prescribed 3,707 times in its second week, while Wegovy recorded 3,071 prescriptions in its first full week and 18,410 the following week.
Eli Lilly shares fell 2.6% at 9:35 a.m. in New York, while Novo Nordisk shares rose 4% in Denmark.
Analysts said the slower ramp would be viewed negatively, prompting investors to cut Foundayo’s 2026 sales forecast to $1.3-$1.5 billion, a level needing about 300,000 prescriptions by year-end.